Class Action Filed Against aTyr Pharma, Inc. (ATYR) Seeking Recovery for Investors - Contact Levi & Korsinsky
ATYRNEW YORK, Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely...
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ATYRBENSALEM, Pa., Nov. 7, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). IF YOU ARE AN INVESTOR WHO...
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
ATYR(NASDAQ:ATYR) LOS ANGELES--(BUSINESS WIRE)---- $ATYR--aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
ATYRaTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
ATYRaTyr Pharma Announces Findings From Interim Analysis Of Eight Patients In Ongoing Phase 2 EFZO-CONNECT Study Evaluating Efzofitimod In SSc-ILD Patients
ATYRHC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
ATYRaTyr Pharma Advances ATYR0101 To IND Candidate Stage For Pulmonary Fibrosis; Preclinical Data Demonstrate ATYR0101's Unique Anti-fibrotic Mechanism Through Interaction With LTBP-1
ATYRaTyr Pharma Q1 EPS $(0.17) Beats $(0.19) Estimate
ATYRHC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
ATYRaTyr Pharma Q4 EPS $(0.18) Beats $(0.23) Estimate
ATYRAtyr Pharma Announces A Publication Demonstrating The Mechanism Of Action For Its Lead Therapeutic Candidate, Efzofitimod, In The Journal Science Translational Medicine
ATYRaTyr Pharma Announces Fourth DSMB Review For Efzofitimod In Phase 3 EFZO-FIT Study In Pulmonary Sarcoidosis
ATYRThis aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
ATYRLeerink Partners Initiates Coverage On aTyr Pharma with Outperform Rating, Announces Price Target of $16
ATYRaTyr Pharma To Present Poster sOn ATYR0101 At Keystone Symposia on Fibrosis Dec. 8-11
ATYR